JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···
Amgen Inc. is a biotechnology company dedicated to providing biological therapeutics to patients with serious diseases by discovering, developing, manufacturing, and delivering innovative human therapies.
Harbour BioMed declared that the U.S. FDA has given the go-ahead for the IND application, permitting the initiation of clinical studies for its inaugural Antibody Drug Conjugate (ADC) project, HBM9033.
This article summarized the latest R&D progress of Bromocriptine Mesylate, the Mechanism of Action for Bromocriptine Mesylate, and the drug target R&D trends for Bromocriptine Mesylate.
Alkermes Plc is a biopharmaceutical company focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction, and multiple sclerosis.
The FDA has given Mallinckrodt the green light to market Lisdexamfetamine Dimesylate Capsules, a product intended to mitigate Attention-Deficit/Hyperactivity Disorder (ADHD).
On September 1, 2023, the NMPA officially approved a new indication for AstraZeneca's blood cancer product, Acalabrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
On September 1, 2023, Mabspace Biosciences registered an international multicenter Phase III clinical trial on the Drug Clinical Trial Registration and Information Publicity Platform.